Moderna turns to biotech startup to ramp up Covid vaccine manufacturing

Moderna will turn to a biotech startup, National Resilience, to manufacture additional doses of its Covid-19 vaccine. Moderna had previously said it would manufacture 800 million to 1 billion doses of its Covid-19 vaccine in 2021, ramping up to 3 billion doses in 2022. A person familiar with the company said the collaboration might result in hundreds of millions more doses. Currently, the vaccine is given as a two-dose series, though Moderna has said at least some patients may need a third dose given many months later. National Resilience will manufacture mRNA to produce the Moderna Covid-19 vaccine at its facility in Mississauga, Ontario, for worldwide distribution. The company is headquartered in San Diego and Cambridge, Mass.